Showing 1161-1170 of 1349 results for "".
- Phase 3 Results Promising for Oral Psoriasis Agenthttps://practicaldermatology.com/news/20140422-phase_3_results_promising_for_oral_psoriasis_agent/2459260/Results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program indicate that the investigational oral Janus kinase (JAK) inhibitor tofacitinib (Pfizer) is both safe and effective for patients with moderate to severe psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 stu
- Residents Provided with Online Education by ASDShttps://practicaldermatology.com/news/20140416-residents_provided_with_online_education_by_asds/2459270/Kyle M. Coleman, MD, has developed a dermatologic surgery educational series as part of the ASDS Future Leaders Network. The "Better Surgical Education" video series, focusing on dermatologic surgery topics and procedures, will provide additional education opportunities for residency programs.
- L'Oreal Partners with Celebrities for New Melanoma PSAhttps://practicaldermatology.com/news/20140416-loreal_partners_with_celebrities_for_new_melanoma_psa/2459271/L'Oréal is partnering with Melanoma Research Alliance (MRA) to launch the campaign "It's THAT Worth It™." Diane Keaton, skin cancer survivor will be featured urging women of all skin tones to use sunscreen. Other celebrities join Keaton in this campaign in print and broadcast PSAs
- Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancerhttps://practicaldermatology.com/news/20140331-frost__sullivan_commends_sensus_for_the_development_of_srt-100_and_srt-100_vision_its_low-energy_radiation_therapy_systems_for_treating_skin_cancer/2459289/Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two lo
- Practical Dermatology® Magazine Names Neal Bhatia, MD, FAAD Co-Chief Medical Editorhttps://practicaldermatology.com/news/20140117-practical_dermatology_magazine_names_neal_bhatia_md_faad_co-chief_medical_editor/2459367/Neal Bhatia, MD, FAAD, San Diego-based dermatologist and well known lecturer and author, has been named Co-Chief Medical Editor of Practical Dermatology® magazine from Bryn Mawr Communications III, LLC. Now in it's 11th year of publicat
- Topical Nitric Oxide Shows Promisehttps://practicaldermatology.com/news/20131212-topical_nitric_oxide_shows_promise/2459395/Novan is kicking off a two-year program to support the pharmaceutical development of Nitric Oxide Advanced Healing (NOAH) technology, including formulation work, nonclinical toxicology, and proof of concept studies in models of deep partial-thickness and full-thickness thermal injuries. The
- Cutera Announces Enhancements to its Sales and Marketing Organizationhttps://practicaldermatology.com/news/20131127-cutera_announces_enhancements_to_its_sales_and_marketing_organization/2459400/Cutera, Inc. recently announced enhancements to its sales and marketing organization. Kevin Connors, President and CEO of Cutera, stated, "We are pleased with our portfolio of product offerings and ex
- LEO Pharma Expands QualityCareTM Patient Support Programhttps://practicaldermatology.com/news/20131126-leo_pharma_expands_qualitycaretm_patient_support_program/2459403/LEO Pharma Inc. has expanded its QualityCareTM Program, a free and confidential patient support service for people affected by psoriasis or actinic keratosis. In addition to live nurse support through the www.qualitycarebyleo.com, the website also allows patients to choose relevant topics of interes
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chro